DGAP-News: MPH Mittelständische Pharma Holding AG

DGAP-News: MPH Mittelständische Pharma Holding AG: Preliminary IFRS results 2015, sales of EUR 264 million, equity of EUR 139.26 million - EUR 3.25 per share

DGAP-News: MPH Mittelständische Pharma Holding AG / Key word(s): Preliminary Results/Final Results MPH Mittelständische Pharma Holding AG: Preliminary IFRS results 2015, sales of EUR 264 million, equity of EUR 139.26 million - EUR 3.25 per share

22.03.2016 / 09:26 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

MPH Mittelständische Pharma Holding AG:

Preliminary IFRS results 2015, sales of EUR 264 million, equity of EUR 139.26 million - EUR 3.25 per share

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), reports its preliminary IFRS Group results for the financial year 2015.

In the financial year 2015 the preliminary IFRS Group sales amounted to approximately EUR 264 million (previous year: EUR 219.25 million).

For the first time MPH reports as an investment entity according to IFRS 10.

Through this report hidden reserves are boosted and recognized through statement of income. The preliminary net income from the transitional consolidation reporting amounts to approximately EUR 87 million (previous year: EUR 8.45 million). The preliminary IFRS earnings per share totalled around EUR 2 (previous year: EUR 0.19)

From now on, the shares of our investments HAEMATO AG, M1 Beauty AG, and CR Capital Real Estate AG that are listed on the Frankfurt Stock Exchange, are valued in the MPH reporting at the XETRA closing price at the end of each quarter. Thereby, the substance and the equity become more transparent. The preliminary equity rose to EUR 139.26 million (previous year: EUR 94.73 million) and amounts to about EUR 3.25 per share.

The business strategy of "making a contribution towards maintaining healthcare affordable", has paid off. In the healthcare market MPH AG is following this investment strategy.

About MPH Mittelständische Pharma Holding AG:

The MPH AG is an investment entity strategically focused on the purchase, development and sale of companies and shares in companies especially from the growth segments of the healthcare market. This includes insurance reimbursed segments as well as privately financed segments. But also beyond the healthcare market MPH makes use of potentials of high growth areas.

Key figures for the share of MPH Mittelständische Pharma Holding AG: Subscribed capital: EUR 42,813,842 Listed shares: ordinary shares ISIN: DE000A0L1H32 WKN: A0L1H3 Stock symbol: 93M

Contact: Linda Reichelt MPH Mittelständische Pharma Holding AG Grünauer Straße 5 D-12557 Berlin

Phone: +49 (0) 30 897308660 Fax: +49 (0) 30 897308669 E-Mail: ir@mph-ag.de Web: www.mph-ag.de

---------------------------------------------------------------------------

22.03.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English Company: MPH Mittelständische Pharma Holding AG Grünauer Straße 5 12557 Berlin Germany Phone: 030 / 897 308 660 Fax: 030 / 897 308 669 E-mail: info@mph-ag.de Internet: www.mph-ag.de ISIN: DE000A0L1H32 WKN: A0L1H3 Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart; Open Market (Entry Standard) in Frankfurt End of News DGAP News Service ---------------------------------------------------------------------------

447597 22.03.2016